EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features

Won Suk Lee, Seonjeong Woo, Sung Hwan Lee, Gae Hoon Jo, Ilhwan Kim, Hyeyeong Kim, Chansik An, Sanghoon Jung, Gwangil Kim, Haeyoun Kang, Beodeul Kang, Jung Sun Kim und 14 weitere

Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 258-275

DOI: 10.3350/cmh.2025.0792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von Won Suk Lee und 25 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Hepatocellular carcinoma (HCC) exhibits substantial morphological and biological heterogeneity. Clinical and molecular relevance of the infiltrative subtype remains poorly defined in the context of cancer immunotherapy. We aimed to evaluate the prognostic impact and molecular features of infiltrative HCC in patients treated with first-line atezolizumab plus bevacizumab (Ate/Bev).

Methods

We included 307 patients with advanced HCC treated with Ate/Bev and classified them into four gross morphological types based on imaging. Multi-omics profiling was conducted on tumor samples. Type IV infiltrative signature was derived and externally validated using five independent HCC cohorts, including IMbrave150.

Results

Infiltrative morphology, encompassing pure and mixed forms, was present in 42.7% of advanced HCC and associated with advanced disease features and compromised liver function. Patients with type IV infiltrative HCC showed lowest objective response rate (14.6%) and worst progression-free (median, 2.8 months) and overall survival (median, 7.1 months). Infiltrative morphology remained an independent predictor of poor outcomes after multivariable adjustment for confounders, including intrahepatic tumor extent. Genomic profiling revealed enriched TP53 and ATM loss-of-function mutations in type IV infiltrative HCC. Transcriptomic and proteomic analyses identified consistent activation of tumor proliferation, epithelial-mesenchymal transition, TGF-β signaling, and immunosuppressive pathways in type IV infiltrative HCC. Type IV infiltrative signature was significantly associated with poor survival across external datasets and retained independent prognostic value.

Conclusions

Infiltrative HCC is a clinically aggressive and molecularly distinct subtype of advanced HCC. Morphological classification and type IV infiltrative signatures may guide risk stratification and therapeutic decision-making in advanced HCC treated with immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDrug Resistance, NeoplasmHumansMaleFemaleMiddle AgedAgedImmunotherapyAntibodies, Monoclonal, HumanizedBevacizumabPrognosisTumor Suppressor Protein p53Gene Expression ProfilingMultiomics

Stichwörter der Autor:innen

Advanced hepatocellular carcinomaGross classificationImmunotherapyInfiltrative morphologyMultiomics analysis

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedBevacizumabTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Department of Life Science, CHA University, Seongnam, Korea.
  • Department of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Department of Radiology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare
  • Ministry of Education
  • BORYUNG Co.
  • Roche
  • DongA ST

Zitieren

APA

Lee, W. S., Woo, S., Lee, S. H., Jo, G. H., Kim, I., Kim, H., An, C., Jung, S., Kim, G., Kang, H., Kang, B., Kim, J. S., Lim, H. Y., Kang, I., Yang, H., Kong, S. J., Son, D., Shin, D. J., Kwon, W. Y., …, & Chon, H. J. (2026). Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features. Clinical and Molecular Hepatology, 32(1), 258-275. https://doi.org/10.3350/cmh.2025.0792

Vancouver

Lee WS, Woo S, Lee SH, Jo GH, Kim I, Kim H, et al. Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features. Clinical and Molecular Hepatology. 2026;32(1):258-275. doi:10.3350/cmh.2025.0792

BibTeX
@article{Lee2026,
  author = {Lee, Won Suk and Woo, Seonjeong and Lee, Sung Hwan and Jo, Gae Hoon and Kim, Ilhwan and Kim, Hyeyeong and An, Chansik and Jung, Sanghoon and Kim, Gwangil and Kang, Haeyoun and Kang, Beodeul and Kim, Jung Sun and Lim, Ho Yeong and Kang, Incheon and Yang, Hannah and Kong, So Jung and Son, Dahyeon and Shin, Dong Jun and Kwon, Woo Young and Lee, Da-Yeon and Lee, Ju-Seog and Park, Junho and Kim, Youngsoo and Hwang, Sohyun and Kim, Chan and Chon, Hong Jae},
  title = {Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {258--275},
  doi = {10.3350/cmh.2025.0792}
}
Kostenlos starten →